{"organizations": [], "uuid": "f28c13bf435c67cf062a5449bf73b61c36169b38", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-announces-d/brief-aralez-pharmaceuticals-announces-discontinuation-of-u-s-commercial-operations-with-reductions-in-operating-expenses-idUSFWN1SF0PH", "country": "US", "domain_rank": 408, "title": "BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T19:10:00.000+03:00", "replies_count": 0, "uuid": "f28c13bf435c67cf062a5449bf73b61c36169b38"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-aralez-pharmaceuticals-announces-d/brief-aralez-pharmaceuticals-announces-discontinuation-of-u-s-commercial-operations-with-reductions-in-operating-expenses-idUSFWN1SF0PH", "ord_in_thread": 0, "title": "BRIEF-Aralez Pharmaceuticals Announces Discontinuation Of U.S. Commercial Operations, With Reductions In Operating Expenses", "locations": [], "entities": {"persons": [{"name": "aralez", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "yosprala", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "aralez pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-aralez pharmaceuticals", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Aralez Pharmaceuticals Inc:\n* ARALEZ ANNOUNCES NEW STRATEGIC DIRECTION * ARALEZ PHARMACEUTICALS INC - DISCONTINUATION OF U.S. COMMERCIAL OPERATIONS, WITH SIGNIFICANT REDUCTIONS IN OPERATING EXPENSES\n* ARALEZ PHARMACEUTICALS INC - FOCUS ON CANADIAN OPERATIONS, SUPPORTED BY TOPROL-XL FRANCHISE REVENUES AND VIMOVO ROYALTIES\n* ARALEZ PHARMACEUTICALS INC - CONCLUDED THAT MOMENTUM FROM ZONTIVITY ALONE IS INSUFFICIENT TO SUSTAIN U.S. COMMERCIAL INFRASTRUCTURE\n* ARALEZ PHARMACEUTICALS INC - ACTIVELY EXPLORING STRATEGIC ALTERNATIVES FOR BUSINESS\n* ARALEZ PHARMACEUTICALS INC - ARALEZ CANADA WILL FOCUS ON DRIVING ORGANIC GROWTH IN CANADA WITH BLEXTEN AND CAMBIA\n* ARALEZ PHARMACEUTICALS INC - ARALEZ EXPECTS CASH OPERATING EXPENSES WILL BE REDUCED TO ABOUT $25 MILLION ON AN ANNUALIZED BASIS\n* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNATIVES INCLUDE ACTIVE DISCUSSIONS TO DIVEST U.S. RIGHTS TO YOSPRALA, FIBRICOR AND BEZALIP SR\n* ARALEZ PHARMACEUTICALS INC - COMPANY CAUTIONS THAT IT HAS VERY RECENTLY EXPERIENCED INCREASED GENERIC COMPETITION WITH RESPECT TO TOPROL-XL FRANCHISE\n* ARALEZ PHARMACEUTICALS INC - STRATEGIC ALTERNTIVES ALSO INCLUDE BROADER STRATEGIC AND REFINANCING ALTERNATIVES FOR ITS BUSINESS\n* ARALEZ PHARMACEUTICALS INC - EVALUATING MARKET DYNAMICS, EXPLORING OPPORTUNITIES TO MITIGATE RISK INVOLVED WITH TOPROL-XL FRANCHISE COMPETITION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T19:10:00.000+03:00", "crawled": "2018-05-09T12:15:42.018+03:00", "highlightTitle": ""}